AARD Stock Summary and Trading Ideas (Aardvark Therapeutics | NASDAQ:AARD)

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Aardvark Therapeutics trades on the NASDAQ stock market under the symbol AARD.

As of April 30, 2026, AARD stock price climbed to $5.26 with 15,596 million shares trading.

AARD has a beta of 4.17, meaning it tends to be more sensitive to market movements. AARD has a correlation of 0.19 to the broad based SPY ETF.

AARD has a market cap of $114.75 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that AARD belongs to (by Net Assets): IWM, VTI, VXF, IBB, IWO.

AARD has underperformed the market in the last year with a return of -54.0%, while the SPY ETF gained +30.2%. In the last 3 month period, AARD fell short of the market, returning -60.6%, while SPY returned +3.2%. However, in the most recent 2 weeks AARD has outperformed the stock market by returning +3.5%, while SPY returned +2.0%.

AARD support price is $4.90 and resistance is $5.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AARD shares will trade within this expected range on the day.